LEXEO Therapeutics
Ronald Crystal is a physician-scientist and pioneer in In vivo gene therapy. He is a Professor and Chairman, Department of Genetic Medicine, Weill Cornell Medical College, previously Chief, Pulmonary Branch, NHLBI. He also directs the Weill Cornell Belfer Gene Therapy Core facility, with 45 faculty/staff, including viral vector, pre-clinical translation, toxicology, regulatory and GMP manufacturing expertise.
Dr. Crystal has 14 approved gene therapy investigational new drug applications with experience in CNS, cardiac, pulmonary and liver human gene therapy.
Dr. Crystal is the founder/co-founder of several gene therapy companies including GenVec, Adverum and XyloCor.
This person is not in any offices
LEXEO Therapeutics
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine.